Skip to main content

CORRECTION article

Front. Neurosci., 31 July 2023
Sec. Translational Neuroscience
Volume 17 - 2023 | https://doi.org/10.3389/fnins.2023.1237920

Corrigendum: Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT)

This article is a correction to:

  1. Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT)

    1. Read original article
\r\nThanh G. Phan, Thanh G. Phan1,2*Rebecca Lim,Rebecca Lim3,4Mirja Krause,Mirja Krause3,4Siow T. Chan,Siow T. Chan3,4Hannah McDonald,Hannah McDonald3,4Poh-Yi Gan,Poh-Yi Gan5,6Shenpeng R. ZhangShenpeng R. Zhang7Liz J. Barreto ArceLiz J. Barreto Arce7Jason Vuong,Jason Vuong1,2Tharani Thirugnanachandran,Tharani Thirugnanachandran1,2Benjamin Clissold,Benjamin Clissold1,2John Ly,John Ly1,2Shaloo Singhal,Shaloo Singhal1,2Marie Veronic Hervet,Marie Veronic Hervet1,2Hyun Ah KimHyun Ah Kim7Grant R. DrummondGrant R. Drummond7Euan M. Wallace,Euan M. Wallace4,8Henry Ma,Henry Ma1,2Christopher G. Sobey Christopher G. Sobey7*
  • 1Clinical Trials, Imaging and Informatics Division, Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia
  • 2Department of Neurology, Monash Health, Clayton, VIC, Australia
  • 3The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia
  • 4Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC, Australia
  • 5Department of Medicine, Centre for Inflammatory Diseases, Monash Medical Centre, School of Clinical Sciences, Monash University, Clayton, VIC, Australia
  • 6Department of Immunology, Monash Health, Monash Medical Centre, Clayton, VIC, Australia
  • 7Department of Microbiology, Anatomy, Physiology and Pharmacology, Centre for Cardiovascular Biology and Disease Research, School of Agriculture, Biomedicine and Environment, La Trobe University, Bundoora, VIC, Australia
  • 8Victorian Department of Health, Melbourne, VIC, Australia

A corrigendum on
Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT)

by Phan, T. G., Lim, R., Krause, M., Chan, S. T., McDonald, H., Gan, P.-Y., Zhang, S. R., Barreto Arce, L. J., Vuong, J., Thirugnanachandran, T., Clissold, B., Ly, J., Singhal, S., Hervet, M. V., Kim, H. A., Drummond, G. R., Wallace, E. M., Ma, H., and Sobey, C. G. (2023). Front. Neurosci. 17:1153231. doi: 10.3389/fnins.2023.1153231

In the published article, there was an error in the author list, and author “Mirja Krause” was erroneously excluded. The corrected author list and author contributions section are appears below.

“Thanh G. Phan1, 2*, Rebecca Lim3, 4, Mirja Krause3, 4, Siow T. Chan3, 4, Hannah McDonald3, 4, Poh-Yi Gan5, 6, Shenpeng R. Zhang7, Liz J. Barreto Arce7, Jason Vuong1, 2, Tharani Thirugnanachandran1, 2, Benjamin Clissold1, 2, John Ly1, 2, Shaloo Singhal1, 2, Marie Veronic Hervet1, 2, Hyun Ah Kim7, Grant R. Drummond7, Euan M. Wallace4, 8, Henry Ma1, 2 and Christopher G. Sobey7*”

Author contributions

TP, HMa, RL, EW, and CS designed the trial protocol and were major contributors in the writing of the manuscript. JV performed image analysis. TT, BC, JL, and SS recruited patients and performed clinical assessments. RL, MK, SC, and HMc prepared cells for administration to patients. MH administered cell infusions and collected the patient data. P-YG, SZ, LB, and HK performed the analyses of blood samples for inflammatory markers. CS and GD analyzed the data. All authors contributed to the article and approved the submitted version.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: stem cell, clinical trial, ischemic stroke, phase I, allogeneic

Citation: Phan TG, Lim R, Krause M, Chan ST, McDonald H, Gan P-Y, Zhang SR, Barreto Arce LJ, Vuong J, Thirugnanachandran T, Clissold B, Ly J, Singhal S, Hervet MV, Kim HA, Drummond GR, Wallace EM, Ma H and Sobey CG (2023) Corrigendum: Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT). Front. Neurosci. 17:1237920. doi: 10.3389/fnins.2023.1237920

Received: 10 June 2023; Accepted: 21 July 2023;
Published: 31 July 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Phan, Lim, Krause, Chan, McDonald, Gan, Zhang, Barreto Arce, Vuong, Thirugnanachandran, Clissold, Ly, Singhal, Hervet, Kim, Drummond, Wallace, Ma and Sobey. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Thanh G. Phan, thanh.phan@monash.edu; Christopher G. Sobey, c.sobey@latrobe.edu.au

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.